期刊文献+

沙利度胺对卵巢癌的化疗前景 被引量:5

Effect prospect of thalidomide in ovarian cancer chemotherapy
下载PDF
导出
摘要 沙利度胺早期曾作为治疗早孕反应的镇静止吐药而广泛被使用,但因其有很强的致畸作用于1963年被停止应用。近年来研究表明,沙利度胺具有免疫调节和抗血管生成作用。对多发性骨髓瘤、急性髓系白血病、子宫肿瘤、前列腺癌等均有一定的疗效,而对其它肿瘤的作用也在进一步研究中。本文对沙利度胺治疗卵巢癌的研究进展做一综述。 Thalidomide as a treatment for early pregnancy has antiemetic and sedative response is widely used, but because there was a strong teratogenic effect in 1963 stopped the application. Recent studies have shown that thalido- mide has a role in immune regulation and anti - angiogenesis. For multiple myeloma, acute myeloid leukemia, uterine cancer, prostate cancer, and so have a certain effect, but also the role of other tumors. In this paper, the effect of tha- lidomide on ovarian cancer was reviewed.
作者 杜娟
出处 《现代肿瘤医学》 CAS 2013年第12期2850-2853,共4页 Journal of Modern Oncology
基金 云南省教育厅资助课题项目(编号:08c0103)
关键词 沙利度胺 卵巢癌 治疗 thalidomide ovarian cancer treatment
  • 相关文献

参考文献25

  • 1Moreira AL,Sampaio EP,Zmuidzinas A. Thalidomide exerts its in- hibitory action on tumor necrosis factor - by enhancing mRNA deg- radation[ J ]. Exp Med, 1993,177 : 1675 - 1680.
  • 2Hung KC, Hsieh PM, Yang KL, et al. Effect of thalidomide on the expression of vascular endothelial growth factor in a rat model of liver regeneration[ J 1. Oncol Lett ,2013,5 ( 3 ) :852 - 856.
  • 3Haslett PA, Corral LG, Albert M, et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing prolifera- tion, cytokine production, and cytotoxic responses in the CD8 sub- set[ J]. Exp Med, 1998,187 : 1885 - 1892.
  • 4Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modu- lates the density of cell surface molecules, involved in the adhesion cascade [ J ]. Immunopharmocology, 1996,31:213 - 221.
  • 5Kobayashi H, Yagyu T, Kondo T, et al. Suppression of urokinase re- ceptor expression by thalidomide is associated with inhibition of nu- clear factor kappaB activation and subsequently suppressed ovarian cancer dissemination[ J]. Cancer Res ,2005,65 : 10464 - 10471.
  • 6He P, Cheng X, Staufenbiel M, et al. Long - term treatment of tha- lidomide ameliorates amyloid - like pathology through inhibition of 13- secretase in a mouse model of Alzheimer's disease [ J]. PloS0ne,2013,8(2) :e55091.
  • 7李文,彭芝兰,曹泽毅.沙立度胺对人卵巢癌细胞株体外生长影响的研究[J].中国实用妇科与产科杂志,2004,20(7):429-430. 被引量:7
  • 8张淼苗,蔡蕾,喇端端.沙利度胺抑制卵巢癌细胞株SKOV3体外生长机制的研究[J].实用医学杂志,2010,26(15):2693-2696. 被引量:6
  • 9杜娟,黄学惠.沙利度胺对裸鼠卵巢癌皮下种植瘤微血管密度和细胞凋亡影响的研究[J].现代妇产科进展,2011,20(1):50-53. 被引量:2
  • 10BoigeV, Malka D, Ducreux M. Therapeutic strategies using VEGF inhibitors in colorectal cancer [ J ]. Bull Cancer, 2005,92 ( Spec- no) :529 -536.

二级参考文献41

  • 1李文,彭芝兰,曹泽毅.沙立度胺对人卵巢癌细胞株体外生长影响的研究[J].中国实用妇科与产科杂志,2004,20(7):429-430. 被引量:7
  • 2苏永忠,谢建英,陈芾珩,吴映娥.沙利度胺对多发性骨髓瘤细胞Survivin表达的影响[J].临床和实验医学杂志,2006,5(5):518-519. 被引量:4
  • 3胡元晶,曲芃芃.VEGF及其受体在上皮性卵巢癌中的表达及与血管生成的关系[J].中国肿瘤临床,2006,33(23):1346-1349. 被引量:10
  • 4Kim YS, Kim JS, Jung HC, et al. The effects of thalido- mide on the stimulation of NF-kappaB activity and TNF- alpha production by lipopolysaceharide in a human colon- ic epithelial cell line[ J ]. Mol Cells ,2004,17:210-216.
  • 5Bergamaschi D, Samuels Y,O'Neil N J, et al. iASPP onto- protein is a key inhibitor of P53 conserved from worm to human [ J ]. Nat Genet, 2003,33 ( 2 ) : 162-167.
  • 6Boige V, Malka D, Ducreux M, et al. Therapeutic strate- gies using VEGF inhibitors in coloreetal cancer [ J ]. Bull Cancer, 2005,92 : 529-536.
  • 7Liu KH, Liao LM, Ro LS, et al. Thalidomide attenuates tumor growth and preserves fast-twitch skeletal muscle fi- bers in cholangiocareinoma rats [ J]. Surgery, 2008, 143 (3) :375-383.
  • 8Holstein SA, Tong H, Hohl RJ. Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibi- tors in multiple myeloma cells [J]. Leuk Res, 2010,34 ( 3 ) : 344-351.
  • 9Giannopoulos K, Dmoszynska A, Kowal M, et al. Thalido- mide exerts distinct molecular antileukemic effects and combined thalidomide/tludarabine therapy is clinically ef- fective in high-risk chronic lymphocytic leukemia [ J ]. Leukemia ,2009,23 (10) : 1771-1778.
  • 10Hales BF. Thalidomide on the comeback trial. Nat Med, 1999, 5(4): 489-490

共引文献23

同被引文献55

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部